Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate is a synthetic nucleotide analog and small molecule with the chemical formula C10H14N5O7P and a molecular weight of approximately 347.22 g/mol[1][2][3][8]. It is not an approved pharmaceutical drug but has been studied experimentally, particularly as a substrate or product in enzymatic reactions related to cobalamin (vitamin B12) biosynthesis. Specifically, it is involved in the activity of nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase (CobT), which catalyzes the synthesis of alpha-ribazole-5'-phosphate from nicotinate mononucleotide and 5,6-dimethylbenzimidazole[1][6]. Additionally, computational studies have suggested that this compound may act as an inhibitor of UBE2C (ubiquitin-conjugating enzyme E2C), indicating potential research interest in oncology or cell cycle regulation[5]. However, there are no clinical trials or approved indications for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate.